Boston Scientific announces launch of Maverick balloon dilatation catheter

PRNewswire -- Boston Scientific Corporation announced that it is launching its unique new Maverick Balloon Dilatation Catheter in the United States. The company believes the Maverick catheter will set a new standard for balloon angioplasty, helping it to continue its leadership in the field.

It is shipping its Over-The-Wire version immediately and will launch the Monorail catheter version shortly.

The Maverick catheter incorporates new materials and new designs of the shaft, balloon and tip to deliver exceptional crossing and tracking performance. It is available across all primary balloon lengths and diameters. In addition to having received U.S. Food and Drug Administration approval, it has also received approval from the Japanese Ministry of Health and Welfare and the CE Mark.

The Maverick catheter features the TrakTip, a soft tubing attached to the end of the balloon via laser bonding to create a flexible tip with a smooth, tapered shape. Unlike previous catheters that featured polyethylene tips, the Maverick catheter's tip is made from nylon-like bumper material that is extremely resilient and exceptionally flexible. Laser bonding precisely applies heat to the bond area resulting in lower profiles, greater flexibility and smoother transitions than previous catheters.

"This is a major new technology platform for balloon catheters,'' said Paul LaViolette, Boston Scientific Senior Vice President and Group President of Cardiovascular. "We are receiving extremely positive physician feedback from our field evaluations. Physicians report that they are very pleased with the Maverick catheter's tracking and crossing abilities.''

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices. The company's products are used in a broad range of interventional medical specialties.

This news release contains forward-looking statements. The company wishes to caution the reader that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and introduction, competitive offerings, intellectual property, the company's overall business strategy, and other factors described in the company's filings with the Securities and Exchange Commission.

Source: Boston Scientific Corporation